Focus on Myelofibrosis Treatment, Which is Better for the Pharma Industry

Myelofibrosis is a bone marrow disease that interrupts the blood cells production process in the body. Fibrous or scar tissue gets developed in the bone marrow leading to scarring causing insufficient blood cell production. Myelofibrosis is a rare type of chronic leukemia affecting blood production. The symptoms of myelofibrosis include severe anemia, fatigue, weakness, and enlarged spleen. The disease is usually found to occur in individuals over the age of 50 years. Myelofibrosis is of two types namely, primary myelofibrosis and secondary myelofibrosis. The treatment options are scarce but the U.S. Food and Drug Administration (FDA) approved Jakafi (Ruxolitinib) in 2011, a drug developed by Novartis, which is the only approved product for the treatment of myelofibrosis that forms a major line of defense against the disease.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/721

Increase in FDA approval of pipeline drugs is expected to drive the market

Growing prevalence of myelofibrosis in developing economies drives the demand for various treatment options for myelofibrosis. The market is expected to grow owing to heavy investments in research and development, appropriate reimbursement conditions, and a large pool of patients living with myelofibrosis. In addition, the market growth can be attributed to other factors including lifestyle up-gradation, unmet medical needs of the patients, increasing incidences of genetic disorders, and escalating smoking population. The market is expected to gain significant traction with the medical advancements focusing patients suffering from myelofibrosis. For instance, development of a molecule, CYT387 or Momelotinib, by Gilead Sciences for treating primary myelofibrosis and the innovation of current drug, ruxolitinib, by Incyte Corporation to develop a substitute dosing strategy in patients with myelofibrosis.

North America to dominate the market with the rising prevalence of myelofibrosis and favorable reimbursement scenario

Regional segmentation of the global myelofibrosis treatment market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to dominate the global myelofibrosis treatment market owing to the growing public awareness, high prevalence of the disease, favorable reimbursement policies, and a higher percentage of the income spent on healthcare. According to the American Society of Hematology 2016, myelofibrosis is a potentially life-threatening blood cancer that affected approximately 20,000 Americans. Asia Pacific is expected to hold a large share of the global market during the forecast period owing to increased disposable incomes, high geriatric population, and improved healthcare facilities.

Access Table of Content (TOC) Of the Report: https://www.coherentmarketinsights.com/ongoing-insight/toc/721

Pipeline drug, Pacritinib, developed by Biopharma reveals higher therapeutic efficacy for myelofibrosis treatment

The key players operating in the global myelofibrosis treatment market include Novartis, Eli Lilly, Roche, Merck & Co., Celgene, Amgen, Bristol-Myers Squibb, Incyte Corporation, and Gilead Sciences. The key players are focused on developing effective treatments that are aimed at easing the patient symptoms with fewer side effects and improving the quality of life. For instance, Biopharma developed Pacritinib in 2016, which is proven to be more effective through the clinical trials than the FDA approved ruxolitinib.

You may be interested

Machine Learning-Based Smartphone App to Evaluate Parkinson’s Symptoms
Information Technology and Gadgets
Information Technology and Gadgets

Machine Learning-Based Smartphone App to Evaluate Parkinson’s Symptoms

Mohit Joshi - September 21, 2018

New smartphone app HopkinsPD, utilizes the smartphone's microphone, touchscreen, and accelerometer to examine patients for symptoms while they perform daily tasks Parkinson’s affects central nervous system of…

Depressive Thoughts Affect Working Memory
Healthcare
Healthcare

Depressive Thoughts Affect Working Memory

Mohit Joshi - September 20, 2018

Researchers establish a link between prolonged depression and reduced working memory, according to a new study published in March 2018. Researchers reveal that dysphoria, which is a…

Myeloproliferative Neoplasms Treatment Market – Current Trends and Future Opportunities by 2026
Healthcare
Healthcare

Myeloproliferative Neoplasms Treatment Market – Current Trends and Future Opportunities by 2026

Albert R - September 20, 2018

Coherent Market Insights added Latest Research Report titled “Myeloproliferative Neoplasms Treatment Market Insights by Manufacturers, Growth, Trends, Regions, Product Type and Application, Geography, Forecast to 2026” to…

Most from this category